new glp 1 agonist novo nordisk expands patient access to authentic, FDA-approved Wegovy® via collaborations with multiple telehealth organizations Novo asks FDA to prevent
Description
doi: 10.3390/ijms242316735

Back UCL (5 Feb 2025) 'GLP-1 drug shows little benefit for people with Parkinson's disease'

Weve heard a lot about glucagon-like peptide 1 (GLP-1) receptor agonists lately, primarily via the brand names Ozempic and Wegovy

The new study found a lower risk for aspiration pneumonia in patients taking GLP-1 medications, compared with people who didnt

Early signs of improvement in liver function Improvements begin relatively soon after starting treatment
Current clinical guidance strongly discourages compounded GLP-1 use